Genetic resistance to popular weight-loss drugs identified: Study explains why some patients don't respond

Scientists have uncovered a genetic reason why some individuals do not respond to widely used weight-loss and diabetes medications. A global genetic study led by Stanford Medicine found that approximately 10% of people possess a specific gene that makes them resistant to the effects of GLP-1 analog drugs.

These medications, including popular treatments like semaglutide and tirzepatide, have revolutionized the management of type 2 diabetes and obesity in recent years. They work by mimicking a hormone that regulates appetite and blood sugar levels, leading to significant weight loss and improved glycemic control for many patients.

The research, which analyzed genetic data from diverse populations worldwide, identified a subtle yet potent genetic resistance. This finding is crucial for understanding treatment variability and could pave the way for more personalized therapeutic approaches in the future. It explains the frustration of patients who, despite adhering to treatment protocols, see little to no benefit from these once-touted miracle drugs.